Goldman Sachs
LKFT

Goldman Sachs’s Lakefront Biotherapeutics American Depositary Shares LKFT Stock Holding History

Goldman Sachs’s Portfolio LKFT Stock Details LKFT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-25,000
Closed -$1.07M – 6103
2022
Q3 		$1.07M Buy
+25,000
New +$1.28M ﹤0.01% 4456
2022
Q1 		– Sell
-22,500
Closed -$1.24M – 6688
2021
Q4 		$1.24M Sell
22,500
-2,400
-10% -$125K ﹤0.01% 4660
2021
Q3 		$1.31M Buy
+24,900
New +$1.48M ﹤0.01% 4550

Other funds holding LKFT

GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
DCM
DME Capital Management New York $3.19B AUM 23.22% 1-Year Est. Return
SBH
Segall Bryant & Hamill Chicago, Illinois $6.98B AUM 34.78% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Goldman Sachs's LKFT Position: Q1 2026 in Review

Goldman Sachs increased its Lakefront Biotherapeutics American Depositary Shares (LKFT) stake by 307% in Q1 2026, buying an estimated $1.13M and bringing the position to 45,371 shares worth $1.36M. The position accounts for ﹤0.01% of the portfolio, ranked #4867.

Goldman Sachs first reported a position in LKFT in Q2 2015 and has held it in 43 quarters since. The position peaked at $23.2M in Q4 2015. 90 funds tracked by Wall St. Rank hold LKFT as of Q1 2026.

  • Goldman Sachs held 45,371 shares of Lakefront Biotherapeutics American Depositary Shares worth $1.36M as of Q1 2026.
  • Goldman Sachs bought 34,227 Lakefront Biotherapeutics American Depositary Shares shares in Q1 2026, an estimated $1.13M.
  • Lakefront Biotherapeutics American Depositary Shares made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #4867 holding.
  • Goldman Sachs first reported a position in Lakefront Biotherapeutics American Depositary Shares in Q2 2015 and has held it in 43 quarters since.
  • Goldman Sachs's Lakefront Biotherapeutics American Depositary Shares position peaked at $23.2M in Q4 2015.
  • 90 funds tracked by Wall St. Rank held Lakefront Biotherapeutics American Depositary Shares as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.